Arcturus Therapeutics To Present At Two Investor Conferences In March

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the "Company", NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that...
Author:
Publish date:

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the "Company", NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne, Chief Executive Officer, will provide a corporate overview at the Cowen & Co. 40 th Annual Healthcare Conference, and the 32 nd Annual ROTH Conference. 

Cowen & Co. 40 th Annual Healthcare Conference Date:                    Monday, March 2Location:              Boston Marriott Copley Place

32 nd Annual ROTH Conference Date:                    Monday, March 16Location:              Ritz-Carlton Laguna Niguel

About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is an RNA medicines company with enabling technologies - LUNAR® lipid-mediated delivery, Unlocked Nucleomonomer Analog (UNA) chemistry, STARR technology™ - and mRNA drug substance along with drug product manufacturing. Arcturus' diverse pipeline of RNA therapeutics includes programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Glycogen Storage Disease Type 3, Hepatitis B, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (182 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc. and the Cystic Fibrosis Foundation. For more information visit www.Arcturusrx.com.

ContactNeda Safarzadeh Arcturus Therapeutics (858) 900-2682 IR@ArcturusRx.com

Arcturus Investor Contacts Michael Wood LifeSci Advisors LLC (646) 597-6983 mwood@lifesciadvisors.com